Delving into the Latest Updates on Beijing Lean Taixiang Technology Development Co. Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Neoplasms

Therapeutic vaccine

Conjugated vaccine

Genetically engineered subunit vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Therapeutic vaccine	1
Conjugated vaccine	1
Genetically engineered subunit vaccine	1

Top 5 Target	Count

EGFR(Epidermal growth factor receptor erbB1)	1

主要目的：在二甲双胍治疗后血糖控制不佳的成人2型糖尿病受试者中评价JY09注射液相对于度拉糖肽注射液治疗26周的疗效差异。次要目的：评价JY09注射液相对于度拉糖肽注射液治疗成人2型糖尿病受试者54周的疗效差异；评价JY09注射液相对于度拉糖肽注射液治疗成人2型糖尿病受试者54周的安全性差异；评价JY09注射液在成人2型糖尿病受试者中的群体药代动力学及暴露-反应关系；评价JY09注射液在成人2型糖尿病受试者中的免疫原性。

[Translation]

Primary objective: To evaluate the efficacy of JY09 injection compared with dulaglutide injection in adult subjects with type 2 diabetes who have poor glycemic control after metformin treatment for 26 weeks. Secondary objectives: To evaluate the efficacy of JY09 injection compared with dulaglutide injection in adult subjects with type 2 diabetes for 54 weeks; To evaluate the safety of JY09 injection compared with dulaglutide injection in adult subjects with type 2 diabetes for 54 weeks; To evaluate the population pharmacokinetics and exposure-response relationship of JY09 injection in adult subjects with type 2 diabetes; To evaluate the immunogenicity of JY09 injection in adult subjects with type 2 diabetes.

Start Date11 Jun 2024

Sponsor / Collaborator

Beijing Oriental Biotech Co., Ltd.

[+1]

CTR20240355 / RecruitingPhase 3

Exendin-4Fc融合蛋白（JY09）注射液在饮食运动干预后血糖控制不佳成人2型糖尿病受试者中的多中心、随机、双盲、安慰剂对照Ⅲ期临床研究

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of exendin-4Fc fusion protein (JY09) injection in adult subjects with type 2 diabetes with poor glycemic control after diet and exercise intervention

主要目的：在仅经饮食运动干预后血糖控制不佳的成人2型糖尿病受试者中评价JY09注射液相对于安慰剂治疗26周的疗效差异次要目的：评价JY09注射液治疗成人2型糖尿病受试者54周的疗效；评价JY09注射液治疗成人2型糖尿病受试者54周的安全性；评价JY09注射液在成人2型糖尿病受试者中的群体药代动力学及暴露-反应关系评价JY09注射液在成人2型糖尿病受试者中的免疫原性。

[Translation]

Primary purpose: To evaluate the efficacy of JY09 injection compared with placebo for 26 weeks in adult subjects with type 2 diabetes who have poor blood sugar control after diet and exercise intervention only Secondary purpose: To evaluate the efficacy of JY09 injection in the treatment of adult subjects with type 2 diabetes for 54 weeks; To evaluate the safety of JY09 injection in the treatment of adult subjects with type 2 diabetes for 54 weeks; To evaluate the population pharmacokinetics and exposure-response relationship of JY09 injection in adult subjects with type 2 diabetes To evaluate the immunogenicity of JY09 injection in adult subjects with type 2 diabetes.

Start Date05 Jun 2024

Sponsor / Collaborator

Beijing Oriental Biotech Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

100 Deals associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data